Objective: Crizotinib is recommended as the first-line therapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Despite its initial efficacy, patients ultimately acquire resistance to crizotinib within 1 year. In such patients, the optimal sequential therapy after crizotinib treatment remains unknown. This study explored which sequential therapy option confers the greatest benefit.
Introduction
Non-small-cell lung cancer (NSCLC) accounts for 80%−85% of lung cancers, most of which are adenocarcinoma (1, 2) . In the past few years, the incidence of adenocarcinoma has dramatically increased, and it has become the predominant histological subtype of lung cancer in most countries (3) . From 2002 to 2012, the Original Article proportion of adenocarcinomas increased from 21.96% to 43.36% (4) . Unfortunately, some patients with NSCLC present with advanced disease at diagnosis, and the median overall survival (OS) is less than 1 year (5) .
Since the discovery of oncogenic driver mutations and the availability of molecular targeted therapy, the management paradigm for patients with NSCLC has drastically changed in the past decade. Genomic rearrangement in anaplastic lymphoma kinase (ALK) receptor tyrosine kinase, a specific molecular subtype of NSCLC, occurs in 5%−7% of patients with NSCLC (6) (7) (8) . However, due to the large population of patients with NSCLC, the absolute number of ALK-positive NSCLC patients is astonishing, with an estimated 40,000 cases occurring worldwide each year (9) . Interestingly, ALK rearrangement is observed predominantly in younger patients and never or light smokers with adenocarcinoma.
Currently, crizotinib is recommended as the first-line standard therapy for ALK-positive advanced or metastatic NSCLC by the National Comprehensive Cancer Network (NCCN) guideline due to its superior efficacy compared with a platinum/pemetrexed doublet therapy in a phase III clinical trial (PROFILE 1014) (10) . However, despite its initial efficacy, patients ultimately acquire resistance to crizotinib within 1 year of treatment initiation which commonly manifests in the form of oligoprogressive metastases (11) . Sequential therapy options beyond disease progression in patients with crizotinib resistance include continuation of crizotinib therapy together with local treatment, next-generation ALK inhibitors (ALKi's), and chemotherapy. However, the optimal sequential therapy options for specific progression patterns in patients with advanced ALK-positive NSCLC after the occurrence of crizotinib resistance have not yet been fully elucidated.
Therefore, this real-world study explored which sequential therapy option confers the greatest benefit in patients with distinct disease progression patterns. Patients were excluded if they had received any previous ALKi therapy other than crizotinib or had progression in multiple metastatic sites. Smokers were defined as current or former smokers while non-smokers were defined as individuals who had smoked <100 cigarettes in their lifetime. Non-liver progression defined as other metastatic sites excluding liver and brain metastases. Data were collected from electronic medical records including clinical and survival data. As an observational study, the present study was exempted from obtaining patients' informed consent but the study was approved by the institutional review board of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Materials and methods

Patients
Treatment
Patients underwent initial treatment with crizotinib at a dosage of 250 mg twice daily. Continuation of crizotinib beyond disease progression was permitted if the patients' clinician had observed clinical benefit. Based on the site of progressive metastases after crizotinib resistance, patients were divided into 3 groups: brain metastases (n=64), nonliver metastases (n=57), and liver metastases (n=17). Sequential therapy mainly included continuation of crizotinib beyond disease progression together with local therapy, next-generation ALKi treatment (ceritinib, alectinib, or AP26113), and chemotherapy. Patients were permitted to cross over to other therapies if progression occurred during the course of treatment.
Outcomes
Disease was assessed at baseline after the first dose of study therapy and repeatedly until radiographic progressive disease (PD) was determined by imaging examination, including a CT scan of the chest and abdomen or MRI of the brain. Thereafter, scan intervals were about every 2 months. Evaluations of the response included complete response (CR), partial response (PR), stable disease (SD), and PD. Both the objective response rate (ORR), defined as patients showing CR and PR, and disease control rate (DCR), defined as patients showing CR, PR and SD, were calculated. Progression-free survival (PFS) was defined as the time from crizotinib treatment to progressive disease, death or last follow-up. The primary endpoint of the study was median OS from the time of crizotinib resistance to death or the date of the last follow-up (31 December, 2017).
Statistical analysis
SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses. Baseline characteristics were presented by applying descriptive statistics. The data for dichotomous variables were presented as the number of patients (n) and percentages (%) and continuous variables were presented as median and range values. The Chisquare test or Fisher's exact test was adopted for dichotomous data comparison among groups. The PFS and OS from the time of crizotinib resistance were analyzed using the Kaplan-Meier method. All statistical tests were two-tailed with P<0.05 considered statistically significant. Variables included age, sex, smoking history, clinical stage, pathological and histological type, ECOG PS scores, the crizotinib therapy line, the progression pattern, and subsequent treatments. GraphPad Prism 6.0 was used to present survival curves.
Results
Baseline characteristics
Of the 157 patients initially enrolled, 19 were excluded as they received no antitumor therapy after the development of crizotinib resistance, and 138 patients were evaluated in the final analysis. The baseline characteristics of the patients are shown in Table 1 . Their median age was 50 (range: 20−83) years, 75 (54.3%) were women, 79 (57.2%) had a good ECOG PS of 0−1, and 98 (71.0%) were nonsmokers with adenocarcinoma. Thirty patients (21.7%) developed with brain metastases before oral crizotinib treatment; 74 received crizotinib as the first-line treatment, and 64 were treated in a second-line setting or later.
Disease progression patterns after crizotinib resistance
In terms of the site of disease progression with crizotinib treatment, the brain was the most common site, accounting for 46.4% of patients. Thirty patients had brain metastases before crizotinib treatment, and 34 patients experienced brain metastatic progression during the course of crizotinib treatment. Other progressions were observed in lung and pleura (26.8% of patients), liver (12.3% of patients), and other metastatic sites (14.5% of patients) ( Figure 1 ).
Survival analysis in patients with distinct progression patterns after crizotinib treatment
Among the 138 patients with advanced ALK-positive NSCLC, the median OS from the time of metastases diagnosis in all patients was 43.4 (95% CI: 32.9−53.8) months, and 16.8 (95% CI: 12.4−21.1) months from the beginning of crizotinib resistance. Among the distinct metastatic sites, no significant differences in the PFS with crizotinib therapy were observed (P=0.646) (Figure 2A ). The PFS with crizotinib therapy was 11.8 months in patients with brain metastases (n=64), 9.6 months in those with non-liver metastases (n=57), and 7.9 months in those with liver metastases (n=17). However, after crizotinib resistance, analyses of OS showed a significant difference among the distinct progression sites (P=0.020). The median OS was 25.4 months in patients with brain metastases, 15.8 months in those with non-liver metastases, and 10.8 months in those with liver metastases ( Figure 2B ).
Sequential therapy options according to patients' distinct progression patterns
The 138 patients were separated into 3 groups according to the sequential therapy administered: 22 patients received chemotherapy, 62 received crizotinib continuation together with local therapy, and 54 received next-generation ALKi's. We further analyzed the OS of different sequential therapy options according to the patients' distinct progression patterns after crizotinib resistance.
Patients with brain metastases
In this group (n=64), chemotherapy was administered to 5 patients, crizotinib continuation treatment with local therapy (which included whole brain radiotherapy or stereotactic radiotherapy) was administered to 36 patients, and next-generation ALKi's were administered to 23 patients. No significant difference in OS was observed among the sequential therapies (P=0.204). The median OS was 32.8 months in patients who received next-generation ALKi therapy, 28.9 months in patients who received crizotinib continuation plus local therapy, and 15.5 months in those who received chemotherapy ( Figure 3A) .
Patients with non-liver metastases
In this group (n=57), chemotherapy was administered to 11 patients, crizotinib continuation with local therapy to 26 patients, and next-generation ALKi's to 20 patients. A statistically significant difference in OS was observed among the various sequential therapies (median OS, 27.6 months with next-generation ALKi's, 13.3 months with crizotinib continuation with local therapy, and 10.8 months with chemotherapy, respectively, P=0.019). Considering crizotinib continuation together with local therapy as a standard treatment, patients who received next-generation ALKi's after crizotinib resistance achieved a longer OS from the time beyond crizotinib resistance (27.6 months vs. 13.3 months, respectively; P=0.033), but no significant difference was found between chemotherapy and crizotinib continuation with local therapy (10.8 months vs. 13.3 months, respectively; P=0.789) ( Figure 3B ).
Patients with liver metastases
In this group (n=17), chemotherapy was administered to 6 patients, crizotinib continuation with local therapy to 5 patients, and next-generation ALKi's to 6 patients. Unlike patients with non-liver metastases, no significant differences in OS were found among the sequential therapies (P=0.061), and those patients receiving nextgeneration ALKi's tended to achieve superior survival, with median OS not reached. The median OS was 10.8 months with crizotinib continuation and 7.0 months with chemotherapy ( Figure 3C ).
Discussion
In this study, we performed a retrospective analysis of PFS with crizotinib and a robust OS estimation of sequential therapies in patients with advanced ALK-positive NSCLC who experienced crizotinib resistance. The median PFS of 10.4 months with crizotinib therapy was shorter than that reported in previous studies (11, 12) . A possible explanation was that 64 (46.4%) patients received chemotherapy before crizotinib treatment, and the benefit of chemotherapy is less than that of crizotinib. We found that the median OS from the time of crizotinib resistance in patients with advanced ALK-positive NSCLC was 16.8 months, which was shorter than that reported in other studies (13, 14) . The reason for the shorter OS in our study was that we calculated OS from the time of crizotinib resistance rather than from the time of the initial diagnosis. In this regard, our study confirmed the results of the PROFILE 1007 (15) and PROFILE 1014 (10) research which concluded that crizotinib confers a long PFS in patients both previously treated and untreated with ALK-positive adenocarcinoma.
Another important finding of our study was that it provided a real-world OS estimation of subsequent therapy options in patients with ALK-positive NSCLC who develop crizotinib resistance according to distinct progression patterns. We showed that the progression patterns with crizotinib resistance in patients with advanced ALK-positive NSCLC varied, and mostly took the form of slowly oligoprogressive metastases. Brain metastases were the most common site following resistance to crizotinib, accounting for 46.4% of our patients. Patients with brain progression in advanced ALK-positive NSCLC still had a longer OS from the time of crizotinib resistance (median 25.4 months) than those with other progression patterns. One reason for the long OS in patients with brain metastases is that the proportion of the study population who received next-generation ALKi's and crizotinib continuation beyond progressive disease was high (92.2%). Another reason is that the mechanism of brain progression may differ from that of other progression sites. This may be related to the low cerebrospinal fluid (CSF)-to-plasma ratio of crizotinib (16) and its low drug penetration into the central nervous system (CNS) in patients whose disease might been sensitive to crizotinib therapy if adequate drug concentrations had been delivered into the CNS (17) . Therefore, patients who experience isolated CNS progression should not be considered as having acquired systemic resistance to crizotinib. In this regard, we found that crizotinib continuation together with local therapy had a non-inferior OS to that of next-generation ALKi treatment. The longer OS from the time of crizotinib resistance in the former group of patients may therefore have been due to their disease being particularly amenable local therapy, including whole brain radiotherapy and stereotactic radiotherapy. Autopsy reports have shown that CNS metastases may remain free of mutations which are associated with secondary resistance (18). Gainor et al. (19) demonstrated that only a minority of ALK-positive patients (about 20%) developed ALK-resistant mutations on crizotinib treatment. Therefore, crizotinib continuation with local therapy might be a feasible strategy after disease progression in patients with brain metastases, as well as next-generation ALKi's.
This study also demonstrated statistically significant differences in OS among different sequential therapy options in patients with non-liver metastases (P=0.019). Patients receiving next-generation ALKi's exhibited a long OS beyond crizotinib resistance (median OS, 27.6 months).
However, in patients with liver metastases, the median OS with next-generation ALKi's was not reached. Although no significant difference in OS was found among the sequential therapy options due to the small sample size, patients with liver metastases receiving next-generation ALKi tended to achieve a long survival. Unlike brain metastases, patients with other progressions might not develop progression due to pharmacokinetic factors. Friboulet et al. (20) reported that the cell line from a liver biopsy which developed in a patient with crizotinib resistance retained sensitivity to crizotinib, but crizotinib failed to achieve antitumor adequate concentrations to completely inhibit ALK and the tumor cell could survive by activation of bypass tracks. This study indicated that nextgeneration ALKi's might have high activity in patients with crizotinib resistance with or without an ALK resistance mutation. Therefore, next-generation ALKi's might be preferred in patients with non-liver progression due to their ability to overcome crizotinib resistance.
Several limitations of our study must be acknowledged. Firstly, this is a single-center retrospective study with a relatively small sample size, especially for liver metastases subgroup, patients receiving next-generation ALKi's tended to achieve a long survival, more cases are needed to confirm our current results. Secondly, patients received local treatment at different time points during the course of crizotinib therapy or before oral crizotinib treatment. Thirdly, we performed neither re-biopsy after the development of resistance nor genomic analysis of progression sites, notably when progressive metastatic lesions occurred in the brain. In the future, a large-scale, prospective, multicenter evaluation is warranted. 
